wanyu/IteraTeR_v2 huggingface dataset:
Original:  The freehiking community claims that the sport is limited to open, unrestricted public areas where off-trail hiking is permitted . Naked hiking See Naked hiking article for more information .
Revised:  The freehiking community claims that the sport is limited to open, unrestricted public areas where off-trail hiking is permitted Naked hiking See Naked hiking article for more information .
Edit intent: fluency
Original:  The freehiking community claims that the sport is limited to open, unrestricted public areas where off-trail hiking is permitted . Naked hiking See Naked hiking article for more information .
Revised:  The freehiking community claims that the sport is limited to open, unrestricted public areas where off-trail hiking is permitted . .
Edit intent: coherence
Original:  Women in the diet intervention group were more likely to report changes in statin use (either cessation or initiation) post-randomization than women in the comparison group   .
Revised:  Women in the diet intervention group were more likely to report changes in statin use (either cessation or initiation) post-randomization than women in the comparison group . .
Edit intent: fluency
Original: Other Ancillary Studies Public health investigators and biostatisticians can apply to use WHI study data in conjunction with their investigations.
Revised: Other ancillary studies Public health investigators and biostatisticians can apply to use WHI study data in conjunction with their investigations.
Edit intent: fluency
Original:  Significant Extension Study Findings Recent analysis during the post-intervention period following the estrogen-plus-progestin trial continues to reveal the strong association between estrogen- plus-progestin usage and breast cancer risk.
Revised:  Significant extension study findings Recent analysis during the post-intervention period following the estrogen-plus-progestin trial continues to reveal the strong association between estrogen- plus-progestin usage and breast cancer risk.
Edit intent: fluency
Original:  Publications and Citations As of September 2018, the WHI has reviewed 3,154 writing proposals, of which 1,725 have been published in scientific journals.
Revised:  Publications and citations As of September 2018, the WHI has reviewed 3,154 writing proposals, of which 1,725 have been published in scientific journals.
Edit intent: fluency
Original:  Awards and Accolades In 2015, the WHI study was awarded the 2015 Team Science Award from the Association for Clinical and Translational Science (ACTS), "given in recognition of the WHI team’s success in the translation of research discoveries into clinical applications and, eventually, widespread clinical practice."
Revised:  Awards and accolades In 2015, the WHI study was awarded the 2015 Team Science Award from the Association for Clinical and Translational Science (ACTS), "given in recognition of the WHI team’s success in the translation of research discoveries into clinical applications and, eventually, widespread clinical practice."
Edit intent: fluency
Original: Significant extension study findings Recent analysis during the post-intervention period following the estrogen-plus-progestin trial continues to reveal the strong association between estrogen- plus-progestin usage and breast cancer risk.
Revised: Significant extension study findings Analysis during the post-intervention period following the estrogen-plus-progestin trial continues to reveal the strong association between estrogen- plus-progestin usage and breast cancer risk.
Edit intent: clarity
Original:   ] In contrast, breast cancer risk was significantly lower for the estrogen-alone group compared to placebo during the post-intervention period.
Revised:  HR] In contrast, breast cancer risk was significantly lower for the estrogen-alone group compared to placebo during the post-intervention period.
Edit intent: fluency
Original:  The Women's Health Initiative, which consisted of three clinical trials (CT) and an observational study (OS) , was conducted to address major health issues causing morbidity and mortality in postmenopausal women .
Revised:  The Women's Health Initiative, which consisted of three clinical trials (CT) and an observational study (OS) .
Edit intent: clarity
Original: Ramzan Paskayev () (born March 16, 1947 in Taraz, Kazakhstan) is a legendary Chechen accordionist and folk musician.
Revised: Ramzan Paskayev () (born March 16, 1947 in Taraz, Kazakhstan) is a Chechen accordionist and folk musician.
Edit intent: clarity
Original: Ramzan Paskayev's affiche In 1967 Paskayev was called to active duty in the ranks of the Soviet Red Army.
Revised:  In 1967 Paskayev was called to active duty in the ranks of the Soviet Red Army.
Edit intent: clarity
Original: Ramzan Sultanovich Paskayev () (born March 16, 1947 in Taraz, Kazakhstan) is a Chechen accordionist and folk musician.
Revised: Ramzan Paskayev () (born March 16, 1947 in Taraz, Kazakhstan) is a Chechen accordionist and folk musician.
Edit intent: clarity
Original: Zeng Jinlian (, June 26, 1964 –February 13, 1982) was the tallest woman verified in modern times , surpassing Jane Bunford's record.
Revised: Zeng Jinlian (, June 26, 1964 –February 13, 1982) was the tallest woman verified in modern times surpassing Jane Bunford's record.
Edit intent: fluency
Original:  In the year between Don Koehler's death and her own , she surpassed fellow "eight-footers" Gabriel Estêvão Monjane and Suleiman Ali Nashnush . Zeng's growth patterns were close to those of Robert Wadlow, as shown in the table below.
Revised:  In the year between Don Koehler's death and her own . Zeng's growth patterns were close to those of Robert Wadlow, as shown in the table below.
Edit intent: clarity
Original: Zeng Jinlian (, June 26, 1964 –February 13, 1982) was second tallest woman verified in modern times  surpassing Jane Bunford's record.
Revised: Zeng Jinlian (, June 26, 1964 –February 13, 1982) was second tallest woman verified in modern times , surpassing Jane Bunford's record.
Edit intent: fluency
Original:  In the year between Don Koehler's death and her own, she surpassed fellow "eight-footers" Gabriel Estêvão Monjane and Suleiman Ali Nashnush.
Revised:  In the year between Don Koehler's death and her own, she surpassed fellow "eight-footers" Don Koehler and Suleiman Ali Nashnush.
Edit intent: clarity
Original: Zeng Jinlian (, June 26, 1964 –February 13, 1982) was the tallest woman verified in modern times, surpassing Anna Hainting Bates's record.
Revised: Zeng Jinlian (, June 26, 1964 –February 13, 1982) was the tallest woman verified in modern times, surpassing Anna Haining Bates's record.
Edit intent: fluency
Original:  In the year between Don Koehler's death and her own, she surpassed fellow "eight-footers" Gabriel Estêvão Monjane and Suleiman Ali Nashnush . Zeng's growth patterns were close to those of Robert Wadlow, as shown in the table below.
Revised:  In the year between Don Koehler's death and her own, she surpassed fellow "eight-footers" Gabriel Estêvão Monjane and Suleiman Ali Nashnush 
Edit intent: coherence
Original:  AgeHeight of Zeng JinlianHeight of Robert Wadlow413161
Edit intent: clarity
Original:  institutional cooperation ;
Revised:  institutional co-operation ;
Edit intent: style
Original: The part of the declaration considered the most troubling was the very last to be mentioned: 'rejecting coercion as an instrument of policy'.
Revised: The part of the declaration considered the most troubling was the last to be mentioned: 'rejecting coercion as an instrument of policy'.
Edit intent: clarity
Original: The Council for International Organizations of Medical Science (CIOMS) The CIOMS, a part of the WHO, is a globally oriented think tank that provides guidance on drug safety related topics through its Working Groups.
Revised: The Council for International Organizations of Medical Science (CIOMS) The CIOMS, a part of the WHO, is globally oriented think tank that provides guidance on drug safety related topics through its Working Groups.
Edit intent: fluency
Original: Pharmacovigilance (PV or PhV ), also known as drug safety, is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products.
Revised: Pharmacovigilance (PV ), also known as drug safety, is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products.
Edit intent: clarity
Original:  The etymological roots for the word "pharmacovigilance" are: pharmakon (Greek for drug) and vigilare (Latin for to keep watch).
Revised:  The etymological roots for the word "pharmacovigilance" are: (Greek for drug) and vigilare (Latin for to keep watch).
Edit intent: clarity
Original:  The etymological roots for the word "pharmacovigilance" are: pharmakon (Greek for drug) and vigilare (Latin for to keep watch).
Revised:  The etymological roots for the word "pharmacovigilance" are: pharmakon (Greek for drug) and (Latin for to keep watch).
Edit intent: clarity
Original:  As such, pharmacovigilance heavily focuses on adverse drug reactions, or ADRs, which are defined as any response to a drug which is noxious and unintended, including lack of efficacy (the condition that this definition only applies with the doses normally used for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological disorder function was excluded with the latest amendment of the applicable legislation).
Revised:  As such, pharmacovigilance heavily focuses on adverse drug reactions, which are defined as any response to a drug which is noxious and unintended, including lack of efficacy (the condition that this definition only applies with the doses normally used for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological disorder function was excluded with the latest amendment of the applicable legislation).
Edit intent: clarity
Original:  Information received from patients and healthcare providers via pharmacovigilance agreements (PVAs) , as well as other sources such as the medical literature, plays a critical role in providing the data necessary for pharmacovigilance to take place.
Revised:  Information received from patients and healthcare providers via pharmacovigilance agreements , as well as other sources such as the medical literature, plays a critical role in providing the data necessary for pharmacovigilance to take place.
Edit intent: clarity
Original:  In fact, in order to market or to test a pharmaceutical product in most countries, adverse event data received by the license holder (usually a pharmaceutical company) must be submitted to the local drug regulatory authority.
Revised:  In order to market or to test a pharmaceutical product in most countries, adverse event data received by the license holder (usually a pharmaceutical company) must be submitted to the local drug regulatory authority.
Edit intent: coherence
Original:  Event refers to an adverse event (AE) . Harm is the nature and extent of the actual damage that could be or has been caused.
Revised:  Event refers to an adverse event . Harm is the nature and extent of the actual damage that could be or has been caused.
Edit intent: clarity
Original:  Individual Case Safety Report (ICSR) is an adverse event report for an individual patient.
Revised:  Individual Case Safety Report is an adverse event report for an individual patient.
Edit intent: clarity
Original:  For instance, obesity is considered a risk factor for a number of different diseases and, potentially, ADRs . Others would be high blood pressure, diabetes, possessing a specific mutated gene, for example, mutations in the BRCA1 and BRCA2 genes increase propensity to develop breast cancer.
Revised:  For instance, obesity is considered a risk factor for a number of different diseases and, potentially, adverse drug reactions . Others would be high blood pressure, diabetes, possessing a specific mutated gene, for example, mutations in the BRCA1 and BRCA2 genes increase propensity to develop breast cancer.
Edit intent: clarity
Original:  Individual Case Safety Report (ICSR) One of the fundamental principles of adverse event reporting is the determination of what constitutes an Individual Case Safety Report (ICSR) . During the triage phase of a potential adverse event report, it is important to determine if the "four elements" of a valid ICSR are present: (1) an identifiable patient, (2) an identifiable reporter, (3) a suspect drug, and (4) an adverse event.
Revised:  Individual Case Safety Report One of the fundamental principles of adverse event reporting is the determination of what constitutes an Individual Case Safety Report (ICSR) . During the triage phase of a potential adverse event report, it is important to determine if the "four elements" of a valid ICSR are present: (1) an identifiable patient, (2) an identifiable reporter, (3) a suspect drug, and (4) an adverse event.
Edit intent: fluency
Original:  Individual Case Safety Report (ICSR) One of the fundamental principles of adverse event reporting is the determination of what constitutes an Individual Case Safety Report (ICSR) . During the triage phase of a potential adverse event report, it is important to determine if the "four elements" of a valid ICSR are present: (1) an identifiable patient, (2) an identifiable reporter, (3) a suspect drug, and (4) an adverse event.
Revised:  Individual Case Safety Report (ICSR) One of the fundamental principles of adverse event reporting is the determination of what constitutes an individual case safety report . During the triage phase of a potential adverse event report, it is important to determine if the "four elements" of a valid ICSR are present: (1) an identifiable patient, (2) an identifiable reporter, (3) a suspect drug, and (4) an adverse event.
Edit intent: fluency
Original:  Individual Case Safety Report (ICSR) One of the fundamental principles of adverse event reporting is the determination of what constitutes an Individual Case Safety Report (ICSR) . During the triage phase of a potential adverse event report, it is important to determine if the "four elements" of a valid ICSR are present: (1) an identifiable patient, (2) an identifiable reporter, (3) a suspect drug, and (4) an adverse event.
Revised:  Individual Case Safety Report (ICSR) One of the fundamental principles of adverse event reporting is the determination of what constitutes an Individual Case Safety Report (ICSR) . During the triage phase of a potential adverse event report, it is important to determine if the "four elements" of a valid individual case safety report are present: (1) an identifiable patient, (2) an identifiable reporter, (3) a suspect drug, and (4) an adverse event.
Edit intent: clarity
Original:  If one or more of these four elements is missing, the case is not a valid ICSR . Although there are no exceptions to this rule there may be circumstances that may require a judgment call.
Revised:  If one or more of these four elements is missing, the case is not a valid individual case safety report . Although there are no exceptions to this rule there may be circumstances that may require a judgment call.
Edit intent: clarity
Original:  If at all possible, it is best to try to obtain the sample which induced the adverse event, and send it to either the EMA , FDA or other government agency responsible for investigating AE reports.
Revised:  If at all possible, it is best to try to obtain the sample which induced the adverse event, and send it to either the European Medicines Agency , FDA or other government agency responsible for investigating AE reports.
Edit intent: clarity
Original:  Expedited reporting This refers to ICSRs ( individual case safety reports ) that involve a serious and unlisted event (an event not described in the drug's labeling) that is considered related to the use of the drug (US FDA).
Revised:  Expedited reporting This refers to individual case safety reports ) that involve a serious and unlisted event (an event not described in the drug's labeling) that is considered related to the use of the drug (US FDA).
Edit intent: clarity
Original:  Expedited reporting This refers to ICSRs ( individual case safety reports ) that involve a serious and unlisted event (an event not described in the drug's labeling) that is considered related to the use of the drug (US FDA).
Revised:  Expedited reporting This refers to ICSRs ( individual case safety reports that involve a serious and unlisted event (an event not described in the drug's labeling) that is considered related to the use of the drug (US FDA).
Edit intent: fluency
Original:  Spontaneous reporting system relies on vigilant physicians and other healthcare professionals who not only generate a suspicion of an ADR , but also report it.
Revised:  Spontaneous reporting system relies on vigilant physicians and other healthcare professionals who not only generate a suspicion of an adverse drug reaction , but also report it.
Edit intent: clarity
Original:  Spontaneous reporting is the core data-generating system of international pharmacovigilance, relying on healthcare professionals (and in some countries consumers) to identify and report any adverse events to their national pharmacovigilance center, health authority (such as EMA or FDA), or to the drug manufacturer itself.
Revised:  Spontaneous reporting is the core data-generating system of international pharmacovigilance, relying on healthcare professionals (and in some countries consumers) to identify and report any adverse events to their national pharmacovigilance center, health authority (such as the European Medicines Agency or FDA), or to the drug manufacturer itself.
Edit intent: clarity
Original:  Hence it is important not only for the patient to report the AE to his health care provider (who may neglect to report the AE), but also report the AE to both the biopharmaceutical company and the FDA, EMA , ...
Revised:  Hence it is important not only for the patient to report the AE to his health care provider (who may neglect to report the AE), but also report the AE to both the biopharmaceutical company and the FDA, European Medicines Agency , ...
Edit intent: clarity
Original:  The individual(s) were not overdosed with any one of the many medications they were taking, but the combination there appeared to cause the AE.
Revised:  The individuals were not overdosed with any one of the many medications they were taking, but the combination there appeared to cause the AE.
Edit intent: clarity
Original:  Signal detection Signal detection (SD) involves a range of techniques (CIOMS VIII).
Revised:  Signal detection Signal detection involves a range of techniques (CIOMS VIII).
Edit intent: clarity
Original:  Individual Case Safety Reports (ICSRs) in these databases are retrieved and converted into structured format, and statistical methods (usually a mathematical algorithm) are applied to calculate statistical measures of association.
Revised:  Individual case safety reports in these databases are retrieved and converted into structured format, and statistical methods (usually a mathematical algorithm) are applied to calculate statistical measures of association.
Edit intent: clarity
Original:  Individual Case Safety Reports (ICSRs) in these databases are retrieved and converted into structured format, and statistical methods (usually a mathematical algorithm) are applied to calculate statistical measures of association.
Revised:  Individual Case Safety Reports (ICSRs) in these databases are retrieved and converted into structured format, and statistical methods (usually a smathematical algorithm) are applied to calculate statistical measures of association.
Edit intent: fluency
Original:  SD is an essential part of drug use and safety surveillance.
Revised:  Signal detection is an essential part of drug use and safety surveillance.
Edit intent: clarity
Original:  Ideally, the goal of SD is to identify ADRs that were previously considered unexpected and to be able to provide guidance in the product's labeling as to how to minimize the risk of using the drug in a given patient population.
Revised:  Ideally, the goal of signal detection is to identify ADRs that were previously considered unexpected and to be able to provide guidance in the product's labeling as to how to minimize the risk of using the drug in a given patient population.
Edit intent: clarity
Original:  Ideally, the goal of SD is to identify ADRs that were previously considered unexpected and to be able to provide guidance in the product's labeling as to how to minimize the risk of using the drug in a given patient population.
Revised:  Ideally, the goal of SD is to identify adverse drug reactions that were previously considered unexpected and to be able to provide guidance in the product's labeling as to how to minimize the risk of using the drug in a given patient population.
Edit intent: clarity
Original:  Risk management plans A risk management plan (RMP)
Revised:  Risk management plans A risk management plan 
Edit intent: coherence
Original:  is a documented plan that describes the risks (adverse drug reactions and potential adverse reactions) associated with the use of a drug and how they are being handled (warning on drug label or on packet inserts of possible side effects which if observed should cause the patient to inform/see his physician and/or pharmacist and/or the manufacturer of the drug and/or the FDA, EMA)) . The overall goal of an RMP is to assure a positive risk-benefit profile once the drug is (has been) marketed.
Revised:  is a documented plan that describes the risks (adverse drug reactions and potential adverse reactions) associated with the use of a drug and how they are being handled (warning on drug label or on packet inserts of possible side effects which if observed should cause the patient to inform/see his physician and/or pharmacist and/or the manufacturer of the drug and/or the FDA, European Medicines Agency . The overall goal of an RMP is to assure a positive risk-benefit profile once the drug is (has been) marketed.
Edit intent: clarity
Original:  is a documented plan that describes the risks (adverse drug reactions and potential adverse reactions) associated with the use of a drug and how they are being handled (warning on drug label or on packet inserts of possible side effects which if observed should cause the patient to inform/see his physician and/or pharmacist and/or the manufacturer of the drug and/or the FDA, EMA)) . The overall goal of an RMP is to assure a positive risk-benefit profile once the drug is (has been) marketed.
Revised:  is a documented plan that describes the risks (adverse drug reactions and potential adverse reactions) associated with the use of a drug and how they are being handled (warning on drug label or on packet inserts of possible side effects which if observed should cause the patient to inform/see his physician and/or pharmacist and/or the manufacturer of the drug and/or the FDA, EMA)) . The overall goal of a risk management plan is to assure a positive risk-benefit profile once the drug is (has been) marketed.
Edit intent: clarity
Original:  Although not necessarily required, RMPs may also be submitted in countries outside the EU.
Revised:  Although not necessarily required, risk management plans may also be submitted in countries outside the EU.
Edit intent: clarity
Original:  The risks described in an RMP fall into one of three categories: identified risks, potential risks, and unknown risks.
Revised:  The risks described in a risk management plan fall into one of three categories: identified risks, potential risks, and unknown risks.
Edit intent: clarity
Original:  Also described within an RMP are the measures that the Market Authorization Holder, usually a pharmaceutical company, will undertake to minimize the risks associated with the use of the drug.
Revised:  Also described within a risk management plan are the measures that the Market Authorization Holder, usually a pharmaceutical company, will undertake to minimize the risks associated with the use of the drug.
Edit intent: clarity